Respiratory Distress Syndrome

Respiratory·MeSH: Respiratory Distress Syndrome

Prevalence

0.1 / 100K

20 drugs in development·14 companies·4 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
eb05	Edesa Biotech, Inc. (EDSA)
exoflo	HCW Biologics Inc. (HCWB)
nogapendekin alfa-inbakicept	ImmunityBio, Inc. (IBRX)
plx-pad	Pluri Inc. (PLUR)
two	GH Research PLC (GHRS)

Phase 2(6)

Drug	Company
allogeneic invariant natural killer t cells	ImmunityBio, Inc. (IBRX)
av-001	Axsome Therapeutics, Inc. (AXSM)
Cell Reconstitution Media	UNITED THERAPEUTICS Corp (UTHR)
Human Mesenchymal Stromal Cells	UNITED THERAPEUTICS Corp (UTHR)
Neuromuscular Blocking Agents	UNITED THERAPEUTICS Corp (UTHR)
Universal Donor TGFβi NK Cells	UNITED THERAPEUTICS Corp (UTHR)

Phase 1(2)

Drug	Company
agent-797	MiNK Therapeutics, Inc. (INKT)
iC9.GD2.CAR.IL-15 T-cells	UNITED THERAPEUTICS Corp (UTHR)

Preclinical(4)

Drug	Company
cb5064 analogs	COHBAR, INC. (COBU)
hemoglobin-based artificial oxygen carriers	SANGUI BIOTECH INTERNATIONAL INC (SGBI)
php-303	Peak Bio, Inc. (PKBO)
sbt102	SANGUI BIOTECH INTERNATIONAL INC (SGBI)

Unknown(2)

Drug	Company
Allogeneic MSC therapy platform	BioCardia, Inc. (BCDA)
NoveCite	Citius Pharmaceuticals, Inc. (CTXR)

Phase 1/Phase 2(1)

Drug	Company
stsa-1002	Eiger BioPharmaceuticals, Inc. (EIGR)

BioSniper tracks 20 drugs in development for Respiratory Distress Syndrome across 14 companies.

There are 4 clinical trials targeting Respiratory Distress Syndrome tracked by BioSniper.

The estimated prevalence of Respiratory Distress Syndrome is approximately 0.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.